Bicara Therapeutics IncBCAX
Price$18.20

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$185.4MTTM through 30 Jun 2026
Free Cash Flow -$135.2MTTM through 30 Jun 2026

Margins

Current

Returns

-34.4%ROE
-32.0%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio14.58x
Net Debt-$414.8Mnet cash position
Cash & Equivalents$96.6M

Quality Metrics

Altman Z-Score19.29
Piotroski F-Score2 / 9
Earnings-Beat Rate25.0%

Multi-Year Trend

Diluted EPS-$3.07TTM
'23'24'25
FY2025: $0.00

Dividend

No dividend

Capital Allocation

R&D Spend$112M

Segment Performance

SegmentRevenueYoYOutlook
Oncology Therapeutics$0
View details

Pivotal Phase 2/3 trial FORTIFI-HN01 is actively enrolling with an interim analysis expected in mid-2027.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.